5 unknown, 2 completed, 2 not yet recruiting, 2 recruiting. 11 Phase 2, 4 Phase 1, 1 Not applicable.
By phase and status
Follow Hellenic Society of Hematology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY
Belantamab Mafodotin, Dexamethasone - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Hellenic Society of Hematology | 14 | 2025-06-20 | 2025-06-13 |
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone - Multiple Myeloma, Neoplasms | Phase 1 / Phase 2 | Recruiting | Hellenic Society of Hematology | 36 | 2023-07-14 | 2023-10-24 |
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Not yet recruiting | Hellenic Society of Hematology | 48 | 2022-10-20 | 2022-10-17 |
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Isatuximab, Pomalidomide, Dexamethasone - Multiple Myeloma, Renal Impairment | Phase 2 | Unknown | Hellenic Society of Hematology | 108 | 2022-05-01 | 2022-03-28 |
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide - Multiple Myeloma, Neoplasms | Phase 1 / Phase 2 | Unknown | Hellenic Society of Hematology | 36 | 2022-04-13 | 2023-12-01 |
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Isatuximab, Bortezomib, Cyclophosphamide - Multiple Myeloma, Renal Impairment | Phase 2 | Unknown | Hellenic Society of Hematology | 51 | 2022-04-01 | 2022-03-29 |
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L
Daratumumab (Subcutaneously) - Primary Plasma Cell Leukemia | Phase 2 | Recruiting | Hellenic Society of Hematology | 43 | 2021-11-19 | 2024-10-10 |
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Belantamab mafodotin - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Hellenic Society of Hematology | 66 | 2021-02-22 | 2023-10-24 |
Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection
Convalescent Plasma - COVID-19 Infection | Not applicable | Completed | National and Kapodistrian University of Athens | 60 | 2020-04-23 | 2024-11-18 |
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Daratumumab, Ixazomib, Dexamethasone - Multiple Myeloma | Phase 2 | Unknown | Hellenic Society of Hematology | 50 | 2018-12-01 | 2018-11-23 |
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
Daratumumab - Multiple Myeloma | Phase 2 | Unknown | Hellenic Society of Hematology | 57 | 2018-02-21 | 2018-03-23 |
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment
Daratumumab with dexamethasone - Relapsed/Refractory Multiple Myeloma | Phase 2 | Completed | Hellenic Society of Hematology | 38 | 2018-02-15 | 2024-03-29 |
Conditions studied
Multiple Myeloma (9) · Blood Protein Disorders (5) · Hematologic Diseases (5) · Neoplasms (5) · Neoplasms, Plasma Cell (5) · Paraproteinemias (5) · Corneal Diseases (3) · Neoplasms by Histologic Type (2) · Renal Insufficiency (2) · COVID-19 (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Recurrence (1)
Interventions
Dexamethasone (8) · daratumumab (6) · Lenalidomide (3) · belantamab mafodotin (2) · isatuximab (2) · pomalidomide (2) · Acetaminophen (1) · Bortezomib (1) · Cyclophosphamide (1) · Diphenhydramine (1) · Ranitidine (1) · darlin protein, Dictyostelium (1) · ixazomib (1) · nirogacestat (1)
Countries
Greece (11)
Top investigators
Evangelos Terpos, Prof (5) · Efstathios Kastritis, Assoc Prof (1) · Evangelos Terpos, Assoc Prof (1) · Evangelos Terpos, MD (1) · Evangelos Terpos, Prof. (1) · Meletios Athanasios Dimopoulos (1) · Meletios-Athanasios Dimopoulos (1)
Results publications
PMID 33920489, PMID 37340832, PMID 38270219, PMID 41346230
NIH funding
2017 (1), 2023 (1)